Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2025 Publisher: Neon Healthcare Limited, 8 The Chase, John Tate Road, Hertford, SG13 7NN, United Kingdom
Hydrea 500 mg Hard Capsules.
| Pharmaceutical Form |
|---|
|
Capsule, hard. Size 0 hard gelatin capsule with an opaque pink body and an opaque green cap, containing a white homogeneous powder. Printed with 'CHP 500' in black ink. |
Each capsule contains 500 mg of Hydroxycarbamide.
Excipients with known effect: Contains Lactose Monohydrate 42.2 mg.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
One of the mechanisms by which hydroxycarbamide acts is the elevation of foetal haemoglobin (HbF) concentrations in sickle cell patients. In addition hydroxycarbamide causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or protein. |
| List of Excipients |
|---|
|
Citric acid, anhydrous Gelatin capsules contain: Erythrosine (E127) |
Carton containing 100 capsules in blisters consisting of PVC/ PCTFE/PVDC and sealed aluminium foil with PVC/PVDC backing.
Neon Healthcare Limited, 8 The Chase, John Tate Road, Hertford, SG13 7NN, United Kingdom
PL 45043/0113
29/05/1986 / 16/12/2002
| Drug | Countries | |
|---|---|---|
| HYDREA | Australia, Brazil, Canada, Estonia, Spain, Finland, France, Ireland, Japan, Lithuania, Mexico, Netherlands, New Zealand, Romania, Tunisia, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.